Zenlabs Ethica Ltd
₹
None%
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd is engaged in trading, marketing and distribution of pharmaceutical formulations.
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Documents
Announcements
-
Closure of Trading Window
28 Jun - Trading window closed from July 1, 2025 till 48 hours post Q1 FY26 results announcement.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 May - Submission of newspaper advertisement for the publication of extract of Audited Financial Results for the Quarter and Year ended on March 31, 2025.
-
Non- Applicability Of Disclosure Of Related Party Transactions For The Half Year Ended On 31St March 2025.
12 May - Disclosure of related party transactions not applicable for half year ended March 31, 2025 due to capital thresholds.
-
Announcement under Regulation 30 (LODR)-Change in Management
12 May - Audited Q4 and FY25 results approved; re-appointed secretarial and internal auditors for FY26.
-
Audited Financial Results For The Quarter And Year Ended On 31St March 2025.
12 May - Audited FY25 results approved; revenue ₹5142L, profit ₹27L; auditors re-appointed with unmodified opinion.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Zenlabs Ethica Ltd is a WHO-GMP certified, third party manufacturing pharma company. Company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada. It is a part of Preet Remedies Group which has five manufacturing units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, minimum order quantity offered is 2000 boxes of drugs.